Tesamorelin vs Semaglutide (and Tirzepatide): Visceral Fat, Appetite, and Whether to Combine Them

Every figure is an all-in monthly price covering the medication, physician review, refill management and shipping. There is no separate membership fee. Semaglutide and tirzepatide are priced by strength, so the figure above is the starting price at the lowest dose. Current pricing always lives on each product page.

No. This is the most common confusion about it. A GLP-1 medication activates the receptor for glucagon-like peptide-1, a gut hormone released after a meal. Tesamorelin activates a different receptor, the growth-hormone-releasing hormone receptor on the pituitary. It does not act on appetite, it does not slow the stomach, and it does not lower blood sugar. If anything it pushes the other way on glucose, because growth hormone reduces insulin sensitivity.

The real difference is the target, not the strength

People ask which is "stronger" for fat loss. That is the wrong comparison. The GLP-1 medications have trials showing large changes in body weight, driven mostly by eating less. Tesamorelin has trials showing a reduction in one fat compartment, the visceral fat inside the abdomen, while body weight barely moved; the approved product's label states it is not indicated for weight-loss management because its effect on weight is neutral. One is a weight tool. The other is a fat-distribution tool. They are not competing for the same job.

Visceral fat sits inside the abdomen around the organs. It is more metabolically active than the fat under the skin and more closely tied to insulin resistance, fatty liver and cardiovascular risk.

The GLP-1 medications reduce fat everywhere, visceral fat included, as a consequence of weight loss. SURMOUNT-5 reported waist circumference falling by double-digit centimetres on both drugs. So someone with a lot of weight to lose and central fat is usually in GLP-1 territory first. Tesamorelin becomes the more specific conversation when the scale is near a healthy range but fat sits around the middle.

Semaglutide or tirzepatide first

The GLP-1 medications are the usual starting point when appetite and total body weight are the problem, within the BMI ranges the trials enrolled: 30 or more, or 27 or more with a weight-related condition. Semaglutide has the longer track record, the larger outcomes trials and the lower price. Tirzepatide acts on two receptors and produced more weight loss in SURMOUNT-5. Semaglutide vs tirzepatide covers that choice in detail.

Tesamorelin

Tesamorelin suits people who are not candidates for a GLP-1 on weight grounds but carry fat centrally, and people who want to work on the growth hormone axis for body composition with training and protein in place. Progress is judged by waist measurement rather than the scale, because the scale is not expected to move much.

They work through unrelated pathways and are sometimes prescribed together, with the GLP-1 addressing total weight and tesamorelin addressing visceral fat. What is known and not known:

• No trial has tested the combination. The evidence for each belongs to that drug alone.
• No trial shows that a growth hormone secretagogue preserves lean mass during GLP-1 treatment. That is a rationale some prescribers give, not a finding.
• Glucose is the point to watch. The GLP-1 lowers it; tesamorelin can raise it. The approved tesamorelin label records new-onset diabetes in 5% of treated patients against 1% on placebo. Anyone using both is monitored for glucose, and anyone already on diabetes medication should say so at intake.
• They are separate prescriptions. No Pepti product puts a GLP-1 and tesamorelin in the same vial. Each keeps its own schedule: the GLP-1 once a week, tesamorelin on weekday nights.

Most people start with one, settle on a dose, and add the second only if there is a reason to. Semaglutide and tirzepatide are not combined with each other.

All three molecules are active ingredients of FDA-approved drugs. The compounded vials Pepti prescribes are not those drugs, and compounded medications are not FDA approved.

The 503B proposal concerns outsourcing facilities that compound in bulk without patient-specific prescriptions; it does not by itself change the 503A pathway under which a pharmacy compounds for a named patient. Are peptides FDA approved explains the difference between not approved and not legal.

All three are injected under the skin (subcutaneously), rotating sites. The schedules are different, and so are the vials.

Tesamorelin. 0.25 mL, which is 25 units on a U-100 insulin syringe, Monday through Friday nights at bedtime. From the 10 mg vial that is 0.5 mg; a 15 mg strength delivers 0.75 mg in the same volume. Bedtime dosing lines the pulse up with the body's largest natural growth hormone pulse during slow-wave sleep. Twenty doses cover four weeks.

Semaglutide. Once weekly, the same day each week. Each strength is a separate dose-specific vial, so the volume changes with the strength: 0.25 mL at the lowest rung, 0.50 mL at the 0.5 mg and 1 mg rungs, and different volumes above that.

Tirzepatide. Once weekly. Every strength from 2.5 mg to 15 mg is 0.50 mL, 50 units.

Both GLP-1s start at the lowest strength and step up, typically at roughly four-week intervals as tolerance allows. You do not need to calculate anything: your physician sets your directions after reviewing your intake, and your directions are printed on the vial. All three ship refrigerated with ice packs and stay in the fridge.

Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

Tesamorelin. On the approved product's label, at 2 mg daily (four times the standard compounded dose), the reactions more frequent than placebo were injection-site reactions (17% against 6%), joint aches, pain in the extremities, muscle aches, peripheral swelling and tingling. The fluid-related effects are classic growth hormone effects and usually mean the dose is higher than the person needs. Glucose can rise.

Semaglutide and tirzepatide. Nausea, diarrhoea, vomiting, constipation and reduced appetite are the most common, mostly during dose increases, usually easing as the body adjusts. Less common but important: pancreatitis, gallbladder disease and dehydration. On insulin or a sulfonylurea, low blood sugar is possible. The approved labels carry a warning about thyroid C-cell tumours seen in rodents.

For all three, stop and contact your physician for any reaction that is severe, spreading, or involves difficulty breathing, and for severe, persistent abdominal pain.

Semaglutide and tirzepatide have the strongest human evidence of anything in the Pepti catalogue, for the branded products those trials studied. Tesamorelin has real randomised trials too, but for visceral fat rather than body weight, mostly in people with HIV, at 1 to 2 mg daily rather than the compounded dose. No trial has tested a compounded vial of any of the three, and no trial has tested tesamorelin together with a GLP-1. Weight tends to return after a GLP-1 is stopped, and visceral fat drifted back toward baseline after tesamorelin was stopped. Any provider attaching a number of pounds or a timeline to any of them is overstating what is known.

None of these can be bought legitimately without a prescription. Sites selling them "for research use only" are not accountable for what is in the vial: identity, purity, sterility and concentration are untested. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a state-licensed, FDA-registered US pharmacy compounds it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and dose changes.

Step-by-step pages: how to get tesamorelin prescribed online, how to get semaglutide prescribed online and how to get tirzepatide prescribed online.